RU2404747C2 - Способ лечения заболеваний предстательной железы, основанный на местной доставке активных веществ - Google Patents

Способ лечения заболеваний предстательной железы, основанный на местной доставке активных веществ Download PDF

Info

Publication number
RU2404747C2
RU2404747C2 RU2007140243/14A RU2007140243A RU2404747C2 RU 2404747 C2 RU2404747 C2 RU 2404747C2 RU 2007140243/14 A RU2007140243/14 A RU 2007140243/14A RU 2007140243 A RU2007140243 A RU 2007140243A RU 2404747 C2 RU2404747 C2 RU 2404747C2
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
prostate
hydroxyflutamide
prostate gland
controlled release
Prior art date
Application number
RU2007140243/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007140243A (ru
Inventor
Ханс ЛЕННЕРНАС (SE)
Ханс ЛЕННЕРНАС
Бо ЛЕННЕРНАС (SE)
Бо ЛЕННЕРНАС
Йонас ХУГОССОН (SE)
Йонас ХУГОССОН
Никлас АКСЕН (SE)
Никлас АКСЕН
Original Assignee
Лиддс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лиддс Аб filed Critical Лиддс Аб
Publication of RU2007140243A publication Critical patent/RU2007140243A/ru
Application granted granted Critical
Publication of RU2404747C2 publication Critical patent/RU2404747C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2007140243/14A 2005-03-31 2006-03-31 Способ лечения заболеваний предстательной железы, основанный на местной доставке активных веществ RU2404747C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
DKPA200500452 2005-03-31

Publications (2)

Publication Number Publication Date
RU2007140243A RU2007140243A (ru) 2009-05-10
RU2404747C2 true RU2404747C2 (ru) 2010-11-27

Family

ID=35044589

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007140243/14A RU2404747C2 (ru) 2005-03-31 2006-03-31 Способ лечения заболеваний предстательной железы, основанный на местной доставке активных веществ

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC7.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC7.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140014294A (cg-RX-API-DMAC7.html)
CN (1) CN101160116B (cg-RX-API-DMAC7.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602776C (cg-RX-API-DMAC7.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC7.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC7.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC7.html)
IL (1) IL185690A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011908A (cg-RX-API-DMAC7.html)
NO (1) NO338679B1 (cg-RX-API-DMAC7.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC7.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
RU2606169C2 (ru) * 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
RU2835869C2 (ru) * 2019-07-31 2025-03-05 Наймокс Корпорейшн Фокальная терапия рака предстательной железы

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016209A2 (en) * 1996-10-16 1998-04-23 Etex Corporation Bioceramic compositions
US5795330A (en) * 1996-10-10 1998-08-18 Etex Corporation Mixing device
WO1999016423A1 (en) * 1997-10-01 1999-04-08 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
WO2004098560A1 (en) * 2003-05-05 2004-11-18 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
GB0307082D0 (en) * 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
PL1680089T3 (pl) * 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795330A (en) * 1996-10-10 1998-08-18 Etex Corporation Mixing device
WO1998016209A2 (en) * 1996-10-16 1998-04-23 Etex Corporation Bioceramic compositions
WO1999016423A1 (en) * 1997-10-01 1999-04-08 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
WO2004098560A1 (en) * 2003-05-05 2004-11-18 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN I. RINI, VIVIAN WEINBERG et al Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer., Journal of Clinical Oncology, 2003, Vol 21, Issue 1, 99-105. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2606169C2 (ru) * 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
RU2835869C2 (ru) * 2019-07-31 2025-03-05 Наймокс Корпорейшн Фокальная терапия рака предстательной железы

Also Published As

Publication number Publication date
EP1865924B1 (en) 2015-12-09
RU2007140243A (ru) 2009-05-10
US8936809B2 (en) 2015-01-20
JP2013067639A (ja) 2013-04-18
WO2006103112A3 (en) 2006-12-21
NO20075490L (no) 2008-01-02
AU2006228675B2 (en) 2012-05-17
KR20080002776A (ko) 2008-01-04
EP1865924A2 (en) 2007-12-19
DK1865924T3 (en) 2016-02-29
WO2006103112A2 (en) 2006-10-05
ZA200708066B (en) 2016-07-27
CN101160116A (zh) 2008-04-09
US20080286205A1 (en) 2008-11-20
NO338679B1 (no) 2016-09-26
PL1865924T3 (pl) 2016-06-30
CN101160116B (zh) 2011-12-07
JP2008534546A (ja) 2008-08-28
HUE026158T2 (en) 2016-05-30
MX2007011908A (es) 2008-02-07
CA2602776C (en) 2013-10-22
JP5635231B2 (ja) 2014-12-03
CA2602776A1 (en) 2006-10-05
KR20140014294A (ko) 2014-02-05
ES2557988T3 (es) 2016-02-01
KR101380402B1 (ko) 2014-04-02
AU2006228675A1 (en) 2006-10-05
IL185690A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
JP2013067639A (ja) 活性物質の局所送達に基づく前立腺疾患の治療方法
JP6445123B2 (ja) 癌を治療するための方法及び組成物
EP1680089B1 (en) Composition comprising biodegradable hydrating ceramics for controlled drug delivery
JP6938462B2 (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
RU2215537C2 (ru) Способ терапевтического лечения доброкачественной гиперплазии простаты или рака простаты млекопитающего
CN102159196B (zh) 治疗上消化道用的药用制剂
JP4845166B2 (ja) ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質
US20030147936A1 (en) Prostatic hormonal implants treatment of prostate cancer
KR20090060306A (ko) 비타민 d 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
Lundgren Progestins in Breast Cancer Treatment: A Reveiw
JP2012517466A (ja) 制御されたドラッグデリバリーのための生体分解性担体を含む組成物
Brogden et al. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
Cheung et al. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations
Goldspiel et al. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer
Begg et al. Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors
EP2152236B1 (en) Pharmaceutical composition of an anthracycline
RU2065307C1 (ru) Способ лечения первичного рака печени и набор для лечения первичного рака печени
KR20250091219A (ko) 위장관의 염증을 치료 및 예방하기 위한 장시간 작용하는 플루티카손 프로피오네이트 주사용 현탁액의 사용
JP2008538580A (ja) 活性ビタミンd化合物またはその模倣体による、化学療法または放射線療法と関連する肺疾患の治療、予防、および改善
US20250040935A1 (en) Fabrication of radiopaque resorbable hydrogel beads via microfluidics for catheter embolization applications
Fosså et al. Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate
Hermosillo-Rodriguez et al. Treatment of Metastatic Cancer: Hormonal Agents, Chemotherapy, Immune Modulation, and Radiopharmaceuticals
Golijanin Early versus late hormone treatment of metastatic prostate cancer
Goya et al. Local injection of a sustained‐release antiandrogen formulation into a target prostatic site: an experimental study
Ito et al. LIMITED EFFECTS OF ANTIANDROGENS AND GONADOTROPIN-RELEASING HORMONE AGONIST ON TRANSPLANTABLE HUMAN PROSTATIC CANCER HONDA